Cargando...
First line nab-paclitaxel plus gemcitabine in elderly metastatic pancreatic patients: a good choice beyond age
BACKGROUND: Nab-paclitaxel plus gemcitabine represents one of the standard regimens for first line treatment of metastatic pancreatic cancer (mPC). Few data are available on nab-paclitaxel plus gemcitabine in geriatric population. Our study aims to show whether this schedule can be feasible in the e...
Gardado en:
| Publicado en: | J Gastrointest Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
AME Publishing Company
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6776800/ https://ncbi.nlm.nih.gov/pubmed/31602329 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2019.06.02 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|